Sep. 12 at 8:12 AM
$XERS This is at the floor of its base valuation, if not below. With profitability on deck Q3/Q4 and no more convertible notes and only the Hayfin loan facility left, this should command a 2 billion market cap by end of year (roughly
$11) or early next year. Yes it's "boring" and somewhat illiquid with only 1-2MM shares traded daily on average, but the swings have consistently printed higher lows and higher highs, and the levo P3 trial is not only fully funded, but also incredibly de-risked, without competition, making the 1 to 3 billion blockbuster launching in 3-4 years very real, as witnessed by Leerink's upgrade from
$12 to
$16. Not a moonshot, but a safe haven in an uncertain market, on track to continuing it's avg. yearly return of 25%, with a sharper rise in pps once the levo trial completion grows nearer. With its cleaned up balance sheet this is also an easy target for big pharma though they may not be for sale. Former
$ESPR peeps, check it out, as always, do your own DD.
